PLAUR encodes the urokinase plasminogen activator receptor (uPAR), a cell-surface glycoprotein that binds urokinase-type plasminogen activator (uPA) and localizes plasmin generation at the cell surface 1. Beyond its enzymatic function, PLAUR mediates proteolysis-independent signaling and regulates cell adhesion, migration, and invasion through extracellular matrix remodeling. The receptor undergoes alternative splicing to produce membrane-bound and soluble isoforms with distinct properties 2. PLAUR dysregulation drives multiple cancer types through distinct mechanisms. In colorectal cancer, FOXM1-driven PLAUR activation promotes tumor growth and metastatic dissemination 3. In gastric cancer, TCF7L2 transcriptionally activates PLAUR to confer anoikis resistance and metastatic capability 4. In hepatocellular carcinoma, PLAUR+ neutrophils establish an immunosuppressive microenvironment that resists anti-PD-1 therapy, and a novel PLAUR inhibitor restores immunotherapy efficacy 5. PLAUR expression is also elevated in rheumatoid arthritis and bronchial asthma, particularly with alternative splicing enrichment in severe asthma 2. Genetic variants in PLAUR associate with myocardial infarction risk in the Chinese Han population 6. PLAUR upregulation during skin wound healing suggests a role in reepithelialization 7. These findings identify PLAUR inhibition as a promising therapeutic strategy, particularly for augmenting immunotherapy in HCC.